US 12,258,394 B2
IL-5 antibody, antigen binding fragment thereof, and medical application therefor
Hua Ying, Shanghai (CN); Jinping Shi, Shanghai (CN); Yifang Wang, Shanghai (CN); Qiyue Hu, Shanghai (CN); Hu Ge, Shanghai (CN); and Weikang Tao, Shanghai (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Lianyungang (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Filed on May 18, 2022, as Appl. No. 17/747,627.
Application 17/747,627 is a division of application No. 16/651,639, granted, now 11,365,247, previously published as PCT/CN2018/108240, filed on Sep. 28, 2018.
Claims priority of application No. 201710906068.X (CN), filed on Sep. 29, 2017.
Prior Publication US 2022/0356239 A1, Nov. 10, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 11/06 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/244 (2013.01) [A61P 11/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A method for inhibiting human IL-5 in a human subject in need thereof, wherein the human IL-5 is associated with a disease selected from the group consisting of asthma, malignant attack of asthma, eosinophilia, Churg-Strauss syndrome, atopic dermatitis, nasal polyps and eosinophilic esophagitis, the method comprising administering to the subject a therapeutically effective amount of an anti-IL-5 antibody or antigen-binding fragment thereof, wherein the anti-IL-5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein:
the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NO: 16, 17 and 18, respectively; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NO: 19, 20 and 21, respectively.